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Bronchiolitis obliterans (BO) is a severe complication after allogeneic hematopoietic stem cell transplantation
with an unfavorable prognosis. Lung biopsy remains the gold standard for diagnosis. In this retrospective
single-center study, we describe 33 patients who underwent biopsy for suspected BO. Ten patients had
constrictive BO (CBO); 9 had lymphocytic bronchiolitis (LB), characterized by lymphocytic inﬁltration of the
bronchioles. Six additional patients (4, CBO; 2, LB) had concomitant infection; 8 had other pathological
diagnoses. Seven patients with CBO and 3 with LB met the National Institutes of Health consensus BO
syndrome deﬁnition criteria. An additional 7 patients with histologically conﬁrmed CBO did not meet the
consensus deﬁnition, 4 of them because of concomitant airway infection. At diagnosis, there were no
signiﬁcant differences between the CBO and LB groups in clinical presentation; pulmonary function tests
(median forced expiratory volume in one second [FEV1] at baseline, 90.4% and 99% predicted, at time of
video-assisted thoracoscopic surgery, 55.1% and 60.8% for CBO and LB groups, respectively); and chest scans.
Treatment was similar in both groups but outcome was different depending on histological ﬁndings. FEV1
signiﬁcantly improved in LB patients compared with CBO patients. Survivals at 1 and 3 years were 77%  12%
and 60%  14% for patients with CBO and 91%  9% for patients with LB (P ¼ .028). Lung biopsy in patients
with suspected BO enables better characterization of the pattern of BO syndrome. In contrast to CBO, LB is
associated with a good long-term prognosis.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION
Despite careful patient selection for hematopoietic stem
cell transplantation (HSCT) and improvements in supportive
care, transplantation-related mortality, mainly due to infec-
tions and graft-versus-host disease (GVHD), remains a major
issue [1-4]. Pulmonary complications are common and are
associated with signiﬁcant morbidity and mortality [4].
Most acute posttransplantation complications are related to
infections, although noninfectious pulmonary toxicity con-
tributes to late complications and are becoming increasingly
recognized [5]. Lung injury can be infectious or noninfec-
tious, acute or chronic, and can manifest with either a
restrictive or an obstructive lung function pattern [6]. Late
pulmonary complications are most often associated with
chronic GVHD [7,8].
Bronchiolitis obliterans syndrome (BOS) is a complication
with an increasing incidence of up to 15% in recent years. The
reason for this increase is not completely understood. It
might be partially explained by more successful treatment of
other posttransplantation complications, thereby exposing
more patients at risk for bronchiolitis obliterans (BO) and
because of an increased use of unrelated donors [9-11]. Indgments on page 979.
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13.03.017addition, differences in the incidence of BOS are in part due
to the diagnostic methods. Risk factors for the development
of BOS include pretransplantation lung function, type and
intensity of the conditioning regimen, use of peripheral
blood stem cells, immunoglobulin levels, and respiratory
infections [12-14]. Moreover, the occurrence of GVHD at
other sites is associated with BOS [15].
The pathogenesis of BO is not completely understood.
Speciﬁc immune reactions by donor T cells, in addition to the
recipient’s innate immune system, are thought to play roles
in the development of BO. According to the National Insti-
tutes of Health (NIH) consensus statement criteria, BO is
considered diagnostic for pulmonary GVHD [16]. BO can be
clinically diagnosed when all of the following criteria are
met: (1) forced expiratory volume in 1 second (FEV1) to
forced vital capacity (FVC) ratio <.7 and FEV1 < 75% of pre-
dicted value; (2) evidence of air trapping or small airway
thickening or bronchiectasis on high-resolution chest
computed tomography (HR-CT), a residual volume >120%, or
a pathological conﬁrmation of constrictive bronchiolitis; and
(3) absence of respiratory tract infection. BO-organizing
pneumonia that is not due to infection, but may represent
a manifestation of either acute or chronic GVHD, is consid-
ered a common feature [16].
Nevertheless, the diagnosis of pulmonary chronic GVHD
remains challenging, and the gold standard remains biopsy-
proven BO [18,19]. However, it is not known if the histology
results of patients with BOS are associated with the severity
of the disease and its outcome. Once diagnosed, intensive,Transplantation.
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for proven BO [17]. However, the prognosis is unfavorable,
mainly because of late deﬁnite diagnosis and resistance to
therapy [18,19]. Progressive deterioration of lung function
and death are common, either due to infections and/or
respiratory failure.
Early testing with prognostic impact is, therefore, urgently
needed. Our hypothesis was that histologymay deﬁne disease
severity and predict the outcomes for patients with BOS. We
therefore reviewed all lung biopsies that were routinely per-
formed in our patients with clinical suspicion of BO. We
analyzed histological patterns, correlations with clinical char-
acteristics, and the potential impact of biopsy results for pre-
dicting patient outcomes and guiding patient management.MATERIALS AND METHODS
Patients and Study Design
This is a single-center cohort study including all consecutive patients
who underwent lung biopsy for suspected BO after allogeneic HSCT from
January 1989 to December 2010. During this period, 917 patients underwent
allogeneic HSCT at our center.
Lung biopsy to diagnose or exclude BO was considered by the treating
physician in patients with respiratory symptoms, declining lung function
test results, or both after exclusion of infections and other differential
diagnoses by HR-CT scan and bronchoalveolar lavage (BAL). Pulmonary
function tests (PFT) were usually performed for each patient using body
plethysmography (Jaeger, Hoechberg, Germany) before transplantation
(baseline); at 3 months, 6 months, and 1, 2 and 5 years after transplantation;
and every 5 years thereafter. Additional PFTwere performed in patients with
pulmonary symptoms that could not be explained by active infections. Total
lung capacity, FVC, FEV1, FEV1:FVC, and the CO diffusion capacity corrected
for the hemoglobin level were determined. Results are reported as
percentage of predicted normal values [20].
BO was considered in the differential diagnosis if a signiﬁcant and
persistent decline (>20% compared to pretransplantation baseline levels) in
FEV1 occurred. However, if the treating physician suspected BOS based on
symptoms and clinical ﬁndings, video-assisted thoracoscopic surgeryFigure 1. Constrictive bronchiolitis obliterans. (A) and (B) Show excentric subepithel
lymphocytic inﬂammation (hematoxylin and eosin, magniﬁcation x200 and 400x, r
separation of the epithelium from the elastic lamina is highlighted in (C). (Elastica va
shows only scattered cytotoxic T-lymphocytes (anti-CD8 immunohistochemical reactio
Carl Zeiss, Jena, Germany).(VATS) was also considered for patients with less pronounced changes in
FEV1. Before surgery, routinework-up included a HR-CTand BAL. HR-CT scan
results were analyzed by an experienced radiologist for intra- and extrap-
ulmonary pathologies, including pulmonary inﬁltrates, bronchial wall
thickening, increased bronchial diameter compared with the accompanying
bronchial artery (bronchiectasis), and air trapping.
All patients underwent BAL to exclude infection as a cause of pulmonary
symptoms and lung function decline. Cytopathological analysis of lavage
ﬂuid included total and differential cell counts and direct staining for
bacterial and fungal organisms. In recent years, we added additional anal-
yses, including immunoﬂuorescence staining for pneumocystis, cytomega-
lovirus, and respiratory syncytial virus (RSV). Microbiological analysis
included viral, bacterial, and fungal cultures. Since February 2009, analytic
sensitivity was increased by analyzing BAL samples with an established
multiplex PCR assay (RespiFinder, Maastricht, The Netherlands). RespiFinder
can detect 14 RNAviruses,1 DNAvirus, and 4 bacteria: adenovirus, Bordetella
pertussis, Chlamydophila pneumoniae, Coronavirus 229E/NL63/OC43, Human
metapneumovirus, inﬂuenza A and B, inﬂuenza A/H5N1, Legionella pneu-
mophila,Mycoplasma pneumoniae, parainﬂuenza (PIV) type 1 to 4, RSV A and
B, and rhinovirus.
Proven infection was not an exclusion criterion for lung biopsy if
patients showed a persistent decline in PFT. Lung biopsies were performed
by VATS, except for the ﬁrst 2 patients who had open lung biopsies. Biopsies
were usually taken from 2 lobes, as well as from the areas most involved on
HR-CT scans. Lung wedge resection was inﬂated and ﬁxed in 4% buffered
formalin. After parafﬁn embedding, specimens were cut into 4-mm sections
and routinely stained with hematoxylin and eosin, Elastica van Gieson,
alcian blue-periodic acid Schiff, and Grocott’s methenamine silver stain. The
specimens were reviewed in a blinded manner by a lung pathologist who
was not involved in the initial diagnosis (L.B. or S.S.). If there were histo-
logical ﬁndings suggestive of a viral infection, such as nuclear enlargement,
clearing, smudging, or multinucleation, immunohistochemical analyses for
cytomegalovirus, herpes simplex virus, or adenovirus were also performed.
Two distinct histological patterns of bronchiolitis were identiﬁed:
constrictive bronchiolitis obliterans (CBO) (Figure 1) and lymphocytic
bronchiolitis (LB) (Figure 2) [21-23]. CBO was characterized by concentric or
eccentric depositions of ﬁbrous tissue within the submucosa of the bron-
chioles, with or without minimal chronic inﬂammation. In contrast, LB was
characterized by a prominent lymphocytic inﬁltration of the bronchiolar
wall with variable epithelial inﬂammation and damage. A third group
comprised patients with other speciﬁc pathological diagnoses.ial deposition of ﬁbrous tissue within the submucosa of a bronchiole without
espectively). In the connective tissue stain, the subepithelial ﬁbrosis and the
n Gieson, magniﬁcation x400). (D) Demonstrates CD8 immunohistochemistry
n, magniﬁcation x400) (Axio Imager A1 microscope; Axio Vision 4.8. Software;
Figure 2. Lymphocytic bronchiolitis. (A) and (B) Show lymphocytic inﬂammation of the bronchiolar epithelium (hematoxylin and eosin, magniﬁcation x200 and
x400, respectively). (C) Shows in the connective tissue stain, the epithelium lies just above the elastic lamina without subepithelial ﬁbrosis (Elastica van Gieson,
magniﬁcation x400). (D) Shows the intraepithelial inﬂammation consists of CD8 positive cytotoxic lymphocytes (anti-CD8 immunohistochemical reaction, magni-
ﬁcation x400) (Carl Zeiss).
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routinely performed.
Therapies and Outcomes
After obtaining biopsy results, all patients with biopsy-proven bron-
chiolitis received new or increased immunosuppressive therapy, including
a calcineurin inhibitor (mainly tacrolimus, except for patients with severe
renal insufﬁciency, for whom sirolimus was used, or intolerance, for whom
cyclosporine was used), mycophenolic acid, and prednisone. Initiation of
prednisone was delayed until 7 to 10 days after surgery to allow wound
healing. Initial dose was usually 2 mg/kg for 14 days, followed by 1mg/kg for
another 2 weeks with subsequent tapering of 10 mg every 2 weeks down to
20 mg daily. Afterwards, steroids were tapered more slowly to 15 mg, 10 mg,
7.5 mg, and 5mg every 4 weeks, depending on stabilization or improvement
of PFT.Mycophenolic acidwas added, based on in vitro data showing a potent
antiproliferative effect on lung ﬁbroblasts [24]. As soon as the systemic
steroid dose was10mg, treatmentwith inhalation steroids twice daily was
started. Azithromycin 500 mg 3 times weekly was added in 2006 after its
anti-inﬂammatory action became evident [25,26]. Type of therapy and
outcome, based on improvement in PFT results, and survival were analyzed.
Data on diagnosis, conditioning regimen, graft source, GVHD prophy-
laxis, smoking history, allergies, and GVHDwere collected retrospectively by
chart review. Follow-ups were current as of July 31, 2011.
Approval from the local institutional review board was obtained for this
study.
Statistical Analysis
Patient survival was determined using the Kaplan-Meier method.
Mann-Whitney U test was used to compare variables among the CBO and LB
groups. For multiple comparisons, Kruskal-Wallis test was used. For
comparisons of FEV1 between CBO, LB, and CBO with infection (CBOi),
analysis of variance was used. For multiple comparisons, a P value of < .01
was considered to be statistically signiﬁcant. For other analyses, a 2-sided P
value of < .05 was considered statistically signiﬁcant. Analyses were per-
formed using IBM SPSS version 19 (IBM, Armonk, NY).
RESULTS
Patient Characteristics
During the last nearly 30 years, surgical lung resections
have been regularly performed at our center in hematologicpatients in neutropenia or posttransplantation. In earlier
years, the main reason for lung resections was fungal infec-
tion [27]. Since 2003, the majority of surgical lung resections
in patients after allogeneic HSCT (ie, in 45 of 59 patients)
have been for diagnostic reasons, early or late after trans-
plantation. Diagnostic questions depended on the time
posttransplantation and clinical characteristics. Twenty-
seven biopsies were performed to diagnose or exclude BO,
which, during this time period, comprised 90% of all patients
in whom BO was suspected based on the criteria described.
Three patients did not proceed to VATS because of either
patient deferral (n ¼ 2) or lung reserve was considered too
poor (n ¼ 1). Biopsies in 6 more patients were performed for
suspicion of BO between 1989 and 2002, representing about
30% of all patients who would have qualiﬁed for this proce-
dure during that time period. Exact reasons for not under-
going lung biopsy could not be ascertained in all cases, but
included both medical reasons (comorbidities, lung function
was considered too poor to allow lung surgery with accept-
able risk) and patient refusal.
Hence, 33 patients for whom a lung biopsy was per-
formed because of an initial suspicion of BO were identiﬁed.
Ten (30%) had histologically proven CBO; 4 (12%) had CBOi
(one with PIV, 3 with RSV); 9 (27%) had LB; and 2 (6%) had LB
with concomitant infection (PIV and RSV, one each). In one
patient, both CBO and LB lesions were identiﬁed. Assuming
that the constrictive lesions would be primarily determining
for the further course of the disease, this patient was
included in our CBO group for further analysis. In the
remaining 8 patients (24%), other histological diagnoses
were made, including mucus plugging (n ¼ 4), organizing
pneumonia (n ¼ 2), veno-occlusive disease of the lung, and
ﬁbrosis (n ¼ 1 each). Patient and disease characteristics are
shown in Table 1.
Table 1
Patient, Disease, and Transplant Characteristics
Characteristic CBO CBO þ Infection LB LB þ Infection Others Total
No. of patients 10 4 9 2 8 33
Males (%) 6 (60%) 2 (50%) 5 (56%) 1 (50%) 6 (75%) 20 (61%)
Diagnosis
PMF 1 0 0 0 0 1
ALL 2 0 4 0 2 8
AML 2 3 3 0 3 11
NHL/CLL 2 0 1 2 2 7
CML 2 1 0 0 1 4
RCC 1 0 0 0 0 1
MDS 0 0 1 0 0 1
Age at diagnosis, median (range), yr 47 (10-59) 45 (15-49) 45 (16-55) 54 (53-55) 45 (18-58) 45 (10-59)
No. of Tx. before allo-HSCT, median (range) 2.5 (0-4) 2.5 (1-3) 4 (1-6) 4 (2-6) 2 (1-8) 3 (0-8)
Patients with previous HSCT
Auto-HSCT 1 0 1 1 1 4
Syngenic-HSCT 1 0 0 0 0 1
Allo-HSCT 0 0 1 0 0 1
Patients with RT before allo-HSCT (%) 2 (20%) 1 (25%) 4 (44%) 0 1 (13%) 8 (24%)
Remission at allo-HSCT*
Early 4 3 6 1 4 18
Intermediate 2 0 0 0 1 3
Advanced 2 1 2 1 0 6
NHL chemosensitive 1 0 0 0 2 3
NHL chemoinsensitive 1 0 1 0 1 3
Age at allo-HSCT, median (range), yr 49 (15-59) 45 (15-49) 46 (17-55) 55.5 (56-57) 46 (19-59) 46 (15-59)
Donor
RD 8 3 6 1 6 24
UD 2 1 3 1 2 9
HLA-match
HLA-identical 9 4 8 2 7 30
HLA-mismatch 1 0 1 0 1 3
CMV (donor/recipient)
/ 5 2 1 1 4 13
/þ 2 1 3 0 2 8
þ/ 1 0 1 0 1 3
þ/þ 2 1 5 1 1 9
Sex match (donor/recipient)
F/M 2 1 3 0 3 9
M/M 4 1 2 1 3 11
M/F 1 1 3 1 1 7
F/F 3 1 1 0 1 6
Stem cell source
BM 1 3 2 0 1 7
PBSC 9 1 7 2 7 26
Conditioning regimen
Intensive 6 4 8 0 7 25
RIC 4 0 1 2 1 8
TBI-based conditioning
200cGy 4 0 1 2 1 8
>/¼ 1000cGy 2 3 5 0 3 13
No 4 1 3 0 4 12
Busulfan-containing conditioning
Yes 3 1 3 0 3 10
No 7 3 6 2 5 23
GVHD-Prophylaxis
CYA 2 1 1 0 2 6
CYA þ MTX 4 3 7 0 5 19
CYA þ MMF 4 0 1 2 1 8
CBO indicates constrictive bronchiolitis obliterans; LB, lymphocytic bronchiolitis; PMF, primary myeloﬁbrosis; ALL, acute lymphoblastic leukemia; AML, acute
myeloid leukemia; NHL/CLL, non-Hodgkin lymphoma/chronic lymphocytic leukemia; CML, chronic myelogenous leukemia; RCC, renal cell carcinoma; MDS,
myelodysplastic syndrome; Tx., therapies; allo-HSCT, allogeneic hematopoietic stem cell transplantation; auto-HSCT, autologous hematopoietic stem cell
transplantation; RT, radiotherapy; RD, related donor; UD, unrelated donor; HLA, human leukocyte antigen; CMV, cytomegalovirus; F, female; M, male; BM, bone
marrow; PBSC, peripheral blood stem cells; RIC, reduced-intensity conditioning; TBI, total body irradiation; Gy, Gray; GVHD, graft-versus-host disease; CYA,
cyclosporine; MTX, methotrexate; MMF, mycophenolate.
Data are presented as n, unless otherwise speciﬁed.
* According to Center for International Blood and Marrow Transplant Research.
A. Holbro et al. / Biol Blood Marrow Transplant 19 (2013) 973e980976Transplantation Characteristics
Table 1 shows the transplantation characteristics based on
the pathological ﬁndings. Median age at transplantation was
46 years (range, 15 to 59 years). Most patients had a matched
related or a 10/10 HLA-matched unrelated donor. Peripheralblood stem cells were the most frequently used stem cell
source. Twenty-ﬁve patients (76%) followed intensive mye-
loablative conditioning regimens, including busulfan for 10
patients (30%). For the majority, GVHD prophylaxis included
cyclosporine and methotrexate (n ¼ 19; 58%).
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Median time interval between HSCT and CBO diagnosis
was 739 days (range, 136 to 3305 days) and, for interval
between HSCT and LB diagnosis, the mean was 550 days
(range, 111 to 2159 days) (P ¼ .253). At diagnosis, the main
symptoms were cough, mainly nonproductive (n ¼ 5 in the
CBO group, n ¼ 6 in the LB group), and dyspnea (n ¼ 9 in the
CBO group, n ¼ 8 in the LB group).
PFT Results
Median baseline FEV1 values before allogeneic HSCTwere
not different between patients who were later diagnosed
with CBO (90.4%; range, 68% to 107%), CBOi (109%; range, 89%
to 120%) or with LB without infection (99%; range, 56% to
114%). (Table 2, Figure 3) Furthermore, at the time of biopsy,
there were no signiﬁcant differences in the median FEV1
values between the 3 groups: CBO, 55.1% (range, 35.2% to
83.2%); CBOi, 41.6% (range, 34.1% to 53.2%); and LB, 60.8%
(range, 44.1% to 85.9%). The median decline in FEV1 from
baseline to the time when biopsy was performed was 43.8%
for CBO, 65.4% for CBOi, and 23.6% for LB. These declines in
PFT were statistically signiﬁcant for all the 3 groups (CBO:
P ¼ .001; CBOi: P ¼ .04; LB: P ¼ .002).
Computed Tomography Findings Before VATS
Three patients had normal HR-CT: 2 in the CBO and 1 in
the LB group. Increased bronchial wall thickening was the
most frequent radiological ﬁnding in both groups: 8 of 10 in
the CBO and 9 of 9 in the LB group. (Table 2) Sixteen (64%)
patients had in- and expiratory HR-CT scans (2 of 4 CBOi
patients, 1 of 4 CBOi patients, 5 of 9 LB patients, and 2 of 2 LBi
patients). Mosaic patterns after expiration or inﬁltrates were
seen in only a few patients. None of the radiological ﬁndings
were pathognomonic for either CBO or LB. Because the
histological diagnosis was known, the sensitivity of CT
ﬁndings could be determined. Among patients with
conﬁrmed CBO, increased bronchial wall thickness wasTable 2
Radiologic Findings, Bronchoalveolar Lavage, and Pulmonary Function Test Results
Results CBO
Symptoms
None 1
Cough 0
Dyspnea 5
Cough and Dyspnea 4
Radiologic ﬁndings
Inﬁltrates 1
Increased bronchial wall thickness 8
Thickness bronchial wall > arterial wall 5
Mosaic pattern 2
Bronchoalveolar lavage ﬁndings*
Cell count, median (range), x106/L 239.55 (
Macrophages, median (range), % 87.5 (
PMN, median (range), % 6 (
Lymphocytes, median (range), % 4 (
Eosinophils, median (range), % 0 (
FEV1 (% predicted), pretransplantation
Mean (range), % 90.8 (
Median, % 90.0
Interquartile ranges 25/50/75 83.5/90.0
FEV1 (% predicted), time of biopsy
Mean (range), % 53.8 (
Median, % 55.0
Interquartile ranges 25/50/75 42.8/55.0
Time to biopsy since transplantation, median (range), days 739 (
CBO indicates constrictive bronchiolitis obliterans; LB, lymphocytic bronchiolitis; P
Data are presented as n unless otherwise indicated.
* Cell differentiation was not available for 2 patients in the CBO and CBO with ifound in 80%, increased bronchial diameter compared with
the corresponding artery in 50%, and a mosaic pattern after
expiration in 29%. The corresponding values in patients with
LB were 100%, 78%, and 20%, respectively.
Table 3 summarizes the NIH-criteria according to the
histological group for each patient.
Bronchoscopy and BAL Results
All patients underwent BAL procedures. Results are
shown in Table 2. Differential cell counts were available for
28 patients (85%). Concomitant viral infection was identiﬁed
in 6 patients (2 with PIV, 4 with RSV). Patients with LB,
compared with patients with CBO, had signiﬁcantly higher
proportions of lymphocytes (P ¼ .009). There were no other
signiﬁcant differences in the differential cell counts between
these 2 groups.
VATS
VATS procedures were performed amedian of 7 days after
BAL. There were no in-hospital and 30-day postoperative
mortalities for the entire group. Twenty-six patients (84%)
did not experience any postoperative complications. Six
patients had surgery-related minor complications: pro-
longed pain (n ¼ 4) and prolonged air leak (n ¼ 1). One
patient experienced pain and hypesthesia after open lung
surgery and another patient developed late empyema (69
days after VATS) that was possibly related to this procedure.
For one intubated patient, the indication for VATS was
persistent pneumothorax with suspected BO; the ﬁnal
diagnosis was veno-occlusive diseases of the lung. This
patient remained intubated and underwent successful
urgent lung transplantation 34 days after VATS.
Therapy
Most patients, all in the CBO group and 8 of 9 (89%) in the
LB group, were treated with calcineurin inhibitors (cyclo-
sporine or tacrolimus). One patient with LB was treated withCBO with Infection LB
0 0
0 1
1 3
3 5
2 2
2 9
2 7
0 1
26-621.9) 69.9 (50.2-89.6) 103.35 (29-830.9)
51-95) 86.5 (86-87) 60 (43-90)
2-45) 9.5 (9-10) 11.5 (0.43)
1-12) 4 (3-5) 14 (6-51)
0-1) 0 1 (0-10)
68-107) 103.0 (89-111) 90.4 (57-114)
109.0 99.0
/100.5 89.0/109.0 75.0/99.0/105.0
35-83) 42.75 (34-53) 62.4 (44-86)
42.0 61.0
/60.3 35.5/42.0/50.8 53.0/61.0/72.0
136-3305) 296 (125-1903) 550 (111-2159)
MN, polymorpho-nuclear cells; FEV1, forced expiratory volume.
nfection group and for one patient in the Others group.
Figure 3. Mean forced expiratory volume in 1 second (FEV1) for the 3 groups
with constrictive bronchiolitis obliterans (CBO), CBO with infection (CBOi), and
lymphocytic bronchiolitis (LB) as percentage of predicted values. The time
points shown are at baseline before hematopoietic stem cell transplantation,
at the time of video-assisted thoracoscopic surgery (diagnosis), and after 3, 6,
12 and 24 month, respectively. Error bar indicates the standard error of the
mean.
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in the CBO and 6 of 9 in the LB group receivedmycophenolate
mofetil as well as macrolides (5 of 10 in the CBO group; 3 of 9
in the LB group). All patients with CBO were treated with
systemic steroids, as were 8 of 9 patients with LB; one of
these was treated with <10 mg/day. Median duration of
steroid treatment with a dosage of 10 mg/day was 32
weeks (range, 8 to 174 weeks) for the CBO and 13 weeks
(range, 0 to 64 weeks) for the LB group. There was only
a slight but not signiﬁcant trend for less intensive steroid
treatment in the LB group (P ¼ .09).Table 3
Histology Versus NIH Criteria
Patient No. Gender NIH Criteria Fulﬁlled Infection FEV1 < 7
CBO
1 M þ  þ
2 M þ  þ
3 F þ  þ
4 M þ  þ
5 M   
6 F þ  þ
7 M þ  þ
8 F   þ
9 M   þ
10 F þ  þ
LB
1 M þ  þ
2 M þ  þ
3 M   þ
4 M þ  þ
5 F   þ
6 F   þ
7 F   
8 M   
9 F   þ
NIH indicates National Institutes of Health; FEV1, forced expiratory volume in 1 s
raphy; CBO, constrictive bronchiolitis obliterans; LB, lymphocytic bronchiolitis; M
Patients with infection were omitted because absence of infection is a prerequisitPatients with infections (either RSV or PIV) were treated
with intravenous immunoglobulins and, for RSV, ribavirin
[28].Follow-Up
Median follow-up time after obtaining a lung biopsy was
715 days (range, 39 to 1914) in the CBO group and 1224 days
(range, 171 to 5666) in the LB group (P ¼ .221). Median
follow-up time after biopsy for surviving patients was 863
days (range, 130 to 1671) in the CBO and 1258 days (range,
453 to 5666) in the LB group (P¼ .38). One patient in the CBO
group underwent lung transplantation; hence, follow-up
was censored at the time of lung transplantation. This
patient is alive 26 months after lung transplantation with an
FEV1 of 106.9% of predicted value.
During follow-up after biopsies, there was no signiﬁcant
increment in the median FEV1 in the CBO and the CBOi
group. In contrast, the LB group exhibited a statistically
signiﬁcant increase in the median FEV1 6 months after
diagnosis (P ¼ .035), maintaining this improvement at 12
months (P ¼ .017). Median FEV1 between the 3 groups
differed statistically upon 6 month after diagnosis. Neither
the CBO nor the CBOi group regained their baseline values
(Figure 3). In the LB group, FEV1 at 3 and 6 months after
diagnosis were also signiﬁcantly lower compared to baseline,
but this difference was no longer detected after 12 and 24
months, when there was only a slight trend for a lower FEV1
compared to baseline. At last follow-up, there was a statisti-
cally signiﬁcant difference in the median FEV1 values
between the 2 groups: CBO, 44.4% (range, 16.8% to 86.7%)
versus LB, 75.3% (range, 50.9% to 116%; P ¼ .014).Survival
For survival analysis, patients with infection present at
the time of diagnosis were included in the corresponding
groups, assuming that after resolution of the initial infection,
survival would be mainly dependent on the histologic char-
acteristics. Figure 4 shows the Kaplan-Meier survival curves5% of Predicted FEV1/FVC < 0.7 RV > 120% HR-CT Criteria
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e for the diagnosis of bronchiolitis obliterans according to the NIH.
Figure 4. Kaplan-Meier survival curves for patients with constrictive bron-
chiolitis obliterans (BO, with and without infection, n ¼ 14) and those with
lymphocytic bronchiolitis (LB, with and without infection, n ¼ 11); P ¼ .028.
A. Holbro et al. / Biol Blood Marrow Transplant 19 (2013) 973e980 979for patients with CBO and LB. Patient survivals at 1 and 3
years were 77% (12%) and 60% (14%), respectively, for
patients with CBO and 91% (9%) for patients with LB (P ¼
.028).
During the observation period, 50% (7 of 14) of the
patients with CBO died, whereas only 9% (1 of 11) of the
patients with LB died. For patients with CBO, the causes of
death were relapse and/or progression of an underlying
disease (n ¼ 3), sepsis (n ¼ 1), respiratory failure (n¼ 2), and
secondary malignancy (n ¼ 1). Sepsis was the cause of death
for the patient with LB. Three of the eight patients with
histological diagnoses other than CBO and LB died during the
follow-up period from respiratory insufﬁciency, secondary
malignancy, or myocardial infarction.DISCUSSION
In this retrospective, single-center study we included all
patients who, after allogeneic HSCT, underwent lung biopsy
for suspected BO. Although the practice for decision-making
was not entirely consistent over the 2 decades and was been
less rigorous in earlier years, a rather strict algorithm has
been followed during the last 10 years, when most of the
biopsies were performed. Even though this study was not
designed to validate the current NIH consensus criteria for
BOS, several important observations can be made.
First, in patients with similar clinical presentation, we
found 2 distinct histological entities: classic CBO character-
ized by depositions of ﬁbrous tissue, and LB characterized by
lymphocytic inﬁltration of the bronchiolar wall without
a signiﬁcant ﬁbrosis. Neither PFT results nor HR-CT ﬁndings
at the time of VATS were predictive for the histologic ﬁnd-
ings. Although BAL showed a signiﬁcantly higher proportion
of lymphocytes in the LB group, this was not found to be
useful for clinical practice, as there was a wide and over-
lapping distribution range.
Second, in our cohort, 7 patients with CBO and 2 with LB
met the current NIH consensus BOS deﬁnition [16]. On the
other hand, 7 patients, 50% of our patient cohort with
histologically conﬁrmed CBO, did not meet the consensus
deﬁnitiond4 of them because of concomitant airway infec-
tion. Furthermore, although this is a small patient number,
signs of air trapping in HR-CT scans were only seen in about
30% of histologically proven CBO. Hence the current deﬁni-
tion includes patients with different histological entities and
may miss some patients with CBO. This may have an impacton the interpretation of therapeutic interventional trial
results if no histologic conﬁrmation of BO is done. If these
results are conﬁrmed, the current NIH consensus BOS deﬁ-
nition may need to be modiﬁed to increase sensitivity. In
addition, the suspicion for evolving BO should remain high
even in the presence of an infection. Finally, our results
conﬁrm that biopsy remains the gold standard for diagnosis
of BO, as outlined in the NIH consensus documents. This
statement is further supported by the fact that we found
other distinct pathological diagnoses in 8 (24%) of our
patients with strong suspicion of BOS. At least some of them
didn’t require intensiﬁed immunosuppressive therapy.
Third, if currently available surgical techniques are
applied by skilled surgeons, VATS can be performed with
a very low complication rate and perioperative risk. These
results compare favorably with previous studies that re-
ported lung biopsy is associated with signiﬁcant morbidity
and mortality, ranging from 13% to 47% [29,30]. Both skilled
surgeons and progress made in minimally invasive surgical
techniques and perioperative patient care might have
contributed to this improvement.
Our study has several limitations. The most important is
its retrospective nature and the small number of patients.
However, because of the rarity of BO and the fact that only
a few centers seek a histological diagnosis, our study is, to the
best of our knowledge, the largest of its kind reported so far.
The retrospective design and the lack of repeated biopsies
during follow-up only allow generating some hypotheses.
Hence it remains an open question if CBO and LB represent 2
different stages of the same disease process or if they are 2
different entities. It seems reasonable that an inﬂammatory
process like LB precedes the ﬁbrosis that is observed in CBO
[31,32], as it has also been described in a case report [33] but
the pathophysiology of CBO remains to be further elucidated.
Because this was not a prospective study, histologic ﬁndings
did not translate yet into different treatment strategies.
Treatment was mainly guided by the further course of PFT.
With similar immunosuppressive treatment, recovery of the
lung function measured by FEV1 and survival were strikingly
different between these 2 groups. Hence, if our hypothesis is
true, our results suggest that intensive immunosuppression
may be able to reverse the pathophysiological process if
bronchiolitis is detected at an early stagewhen inﬂammatory
changes predominate, and prevent the development of
ﬁbrosis, thus altering the otherwise poor prognosis of
evolving BO. When constrictive changes are already estab-
lished, intensive immunosuppression will not lead to im-
provements in airway narrowing, and may even contribute
to further deterioration of lung function by increasing the
susceptibility to infections or increasing the risk for relapse
and/or the development of secondary malignancy. For
these patients, new antiproliferative approaches need to be
investigated.
In conclusion, lung biopsies for patients with suspected
BO better characterize the BOS pattern following allogeneic
HSCT. In contrast to CBO, LB, which may represent an
inﬂammatory status preceding CBO, is associated with
a good long-term prognosis. Further understanding of the
pathophysiology of BOS is necessary to develop appropriate
strategies for the early diagnosis and treatment of this severe
post-transplantation complication.
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